. Author manuscript; available in PMC: 2015 Mar 4.

Published in final edited form as: Lancet Neurol. 2013 Oct 30;12(12):1159–1169. doi: 10.1016/S1474-4422(13)70258-8

Table 2.

Median interferon score in patients, and score by genotype

	Number of patients	Median (IQR)	Patients with positive or negative interferon score
			Positive	Negative
Patients	82	12·90 (6·14–20·41)	74 (90%)	8 (10%)

Controls	29	0·93 (0·57–1·30)	2 (7%)	27 (93%)

TREX1	17	18·19 (9·12–20·46)	16 (94%)	1 (6%)

RNASEH2A	4	18·47 (7·51–34·62)	4 (100%)	0

RNASEH2B	26	6·55 (2·32–12·94)	19 (73%)	7 (27%)

RNASEH2C	4	6·43 (4·54–13·35)	4 (100%)	0

SAMHD1	16	12·81 (10·15–19·57)	16 (100%)	0

ADAR	15	23·39 (14·69–36·39)	15 (100%)	0

RNASEH2B with positive score	19	8·89 (5·32–14·03)	··	··

TREX1, RNASEH2A, RNASEH2C, SAMHD1, ADAR combined	56	1476 (10·53–23·38)	··	··

Patients versus controls, χ² test p<0·0001.